Merck announced that the company board of directors has unanimously elected Robert M. Davis to serve as chairman of the board, effective Dec. 1, 2022. He will succeed Kenneth C. Frazier, who plans to retire on Nov.

30, 2022, after a long-tenured career at Merck that began in 1992. Frazier led the company for 10 years as president and chief executive officer, from 2011 through 2021. He has served as a Merck director since January 2011 and chairman of its board of directors since December 2011.

Davis, who currently serves as president and chief executive officer, became Merck's president in April 2021 and was named Merck's chief executive officer and a member of its board in July 2021. About Robert M. Davis: Rob Davis is chief executive officer and president of Merck. Previously, Rob served as Merck's president, responsible for the company's operating divisions — Human Health, Animal Health, Manufacturing and Merck Research Laboratories.

Prior to that, he was executive vice president, Global Services, and the company's chief financial officer. Rob joined the company as chief financial officer in 2014 with additional responsibility for real estate operations, corporate strategy and business development. In 2016, his role was expanded to include responsibility for information technology and procurement, forming Global Services.

He became president in April 2021 and CEO and a member of the board of directors on July 1, 2021. Prior to joining the company, Rob was corporate vice president and president of Baxter's Medical Products business. During his tenure at Baxter, he held several other positions, including president of Baxter's Renal business, chief financial officer and treasurer.

Before joining Baxter in 2004, Rob held numerous positions of increasing responsibility over 14 years at Eli Lilly and company. Rob serves on the board of directors for Duke Energy Corporation and is chair of its finance and risk management committee and a member of the corporate governance committee. In addition, Rob is a board member of Project Hope, a non-profit organization focused on empowering health care workers to deliver expert care when and where it is needed most.

Rob received his J.D. from Northwestern University School of Law, his M.B.A. from Northwestern University's Kellogg Graduate School of Management and his bachelor's degree in finance from Miami University. About Kenneth C. Frazier: Kenneth C. Frazier has served as executive chairman of Merck's board of directors since July 2021, following his retirement from a decade-long tenure as Merck's president and chief executive officer. Under Ken's leadership, the company delivered innovative life-saving medicines and vaccines as well as long-term and sustainable value to its multiple stakeholders.

Ken substantially increased the company's investment in research, including early research, while refocusing the organization on the launch and growth of key products that provide far-reaching benefits to society. He also led the formation of philanthropic and humanitarian initiatives that build on Merck's 130-year legacy. Ken joined the company in 1992 and held positions of increasing responsibility, including general counsel, before becoming president and chief executive officer in 2011.

Prior to joining Merck, Ken was a partner with the Philadelphia law firm of Drinker Biddle & Reath. Ken's contributions, especially in the legal, business, and humanitarian fields, have been widely recognized. He sits on the boards of Weill Cornell Medicine, Eikon Therapeutics, the National Constitution Center and Cornerstone Christian Academy in Philadelphia, PA.

He is Co-Founder and Co-Chair of OneTen, a coalition of leading organizations committed to upskilling, hiring, and promoting one million Black Americans into family-sustaining jobs. OneTen is committed to facilitating a meaningful, measurable, and lasting impact on racial and economic justice. Ken is also Chairman, Health Assurance Initiatives, at the venture capital firm, General Catalyst, where he advises on investments and partnerships and provides mentorship to founders building companies that are well positioned to transform the healthcare industry through collaborative and responsible innovation.

He also is a member of the American Academy of Arts and Sciences, the American Philosophical Society, The Business Council, the Council of the American Law Institute, the American Bar Association, and a Fellow of the College of Physicians of Philadelphia. Additionally, Ken is Co-Chair of the Legal Services Corporation's Leaders Council. As a strong advocate for social justice and economic inclusion, Ken is the recipient of numerous awards and honors, including the Anti-Defamation League Courage Against Hate Award, the Botwinick Prize in Business Ethics from Columbia Business School, the Legend in Leadership Award from the Yale School of Management, the NAACP Legal Defense and Educational Fund National Equal Justice Award, and the National Minority Quality Forum's Lifetime Achievement Award.

In 2018, Ken received the Harvard Law School Association Award, the highest honor given by the prestigious association, in recognition of his extraordinary service to the legal profession, Harvard Law School, and the public. In that same year, Ken was named one of the World's Greatest Leaders by Fortune magazine and was also named one of TIME's 100 Most Influential People and again made that list in 2021. In 2019, he became the first recipient of the Forbes Lifetime Achievement Award for Healthcare.

In 2021, Columbia Business School honored him with the Deming Cup for Operational Excellence, and his peers named Ken Chief Executive magazine's CEO of the Year. Ken received his bachelor's degree from The Pennsylvania State University and holds a J.D. from Harvard Law School.